Navigation Links
Use of a fast-acting insulin analog to control diabetic ketoacidosis in Children

Diabetic ketoacidosis (DKA) is a life-threatening condition that frequently requires hospitalization in children with type 1 diabetes.// The critical factors in the treatment of DKA include careful and frequent monitoring of the patient, skillful fluid and electrolyte adjustment, and the initiation of insulin therapy after the initial restoration of fluid volume has been achieved. Continuous low-dosage intravenous infusion of soluble insulin has been the procedure of choice for this because it provides direct control and results in a predictable rate of fall in serum glucose levels. However, admission to an intensive care unit to receive intravenous insulin infusion increases health care costs.

A recent study proposes using a subcutaneous fast-acting analog of human insulin instead of intravenous continuous regular insulin to avoid the need for a second intravenous line, simplify treatment of DKA in children, and provide a more economical solution. The aim of the study was to compare the efficacy of a subcutaneous fast-acting analog (lispro) with continuous intravenous regular insulin (CIRI) in the treatment of pediatric DKA.

The fluid replacement protocol aimed at correcting intravascular volume up to the normalization of the peripheral perfusion. Once cardiovascular stability was achieved, the child was alert, and vomiting has stopped, oral rehydration was started. Cerebral edema, the most feared complication of DKA, did not develop in the patients during this study. Also, there were no deaths or "near death" episodes, and no patient had to be treated with mannitol.

The study, published in the August issue of Diabetes Care concludes that DKA treatment with a subcutaneous fast-acting insulin analog represents a cost-effective and technically simplified procedure that precludes intensive care unit admission.


'"/>




Page: 1

Related medicine news :

1. Animal insulin product to be discontinued by drug major Eli Lilly
2. Brain stem cells to help in producing insulin
3. Now insulin can be inhaled
4. Exubera could mean the end of an insulin injection era for diabetics
5. Islet cells producing insulin cultivated in the lab
6. Pfizer vouches safety of long-term inhaled insulin.
7. Uncontrolled blood pressure
8. FDAs control is inherently weak
9. Drugs control and industry departments to share a common e-platform
10. Self control makes stress response easy
11. Progression of Glaucoma could be controlled with early detection
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... , ... April 24, 2017 , ... Sean Fay is ... Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more ... other marketer in the last 25 years. , Now, due to changes in the ...
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum ... allows anyone, anywhere to track their cognitive health, and share results with their physicians. ... brain health on the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at ...
(Date:4/24/2017)... Virginia (PRWEB) , ... April 24, 2017 , ... ... announced that they are seeking public support to bring their novel lifesaving device ... appearance, wearable device packed with medical-grade sensors, specially designed to read a child’s ...
(Date:4/24/2017)... and Waycross, Ga. (PRWEB) , ... April 24, ... ... leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine mobile ... board-certified primary care providers. Available 24 hours a day, Quick Care provides patients ...
(Date:4/24/2017)... ... April 24, 2017 , ... According to the U.S. Centers ... the lives of 62 Americans each day.(1) Yet since 2011, the Drug Enforcement ... and prescribers by more than half.(2) Novus Medical Detox Center , a ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
(Date:4/18/2017)... DUBLIN , April 18, 2017 Research ... Devices Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at ... The report, Global Arthroscopy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Medicine Technology: